8 June 2011
Advanced Medical Solutions Group plc
(“AMS” or “the Company”)
Result of Annual General Meeting
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, held its Annual General Meeting today, at which all resolutions put to shareholders were duly passed.
Chris Meredith, AMS’s Chief Executive Officer, gave a presentation at the AGM, the slides from which will be made available on the Company’s website www.admedsol.com.
–ends –
For further enquiries:
Advanced Medical Solutions Group plc +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Mary Tavener, Finance Director
Tavistock Communications +44 (0) 20 7920 3150
John West / Chris Munden / Andrew Dunn
Investec Bank plc +44 (0) 20 7597 5970
Gary Clarence / Patrick Robb / Daniel Adams
Notes to Editors:
AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.
AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.
This information is provided by RNS
END
RAGSSMFFAFFSEEM